z-logo
open-access-imgOpen Access
The safety of multiple oral immunotherapy in phase one studies at a single center
Author(s) -
Dominguez TLR,
Mehrotra A,
Wilson S,
Winterroth L,
Blakemore A,
Sampson K,
Nadeau K
Publication year - 2013
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-3-s3-o25
Subject(s) - medicine , oral immunotherapy , single center , center (category theory) , immunotherapy , medical physics , family medicine , cancer , chemistry , crystallography
Background There are over 15 million people with food allergies, 38% of which suffer from more than 1 food allergy. With increasing interest in oral immunotherapy (OIT) as a potential treatment, the safety of ingesting known allergens is a major concern. Little to no data are available for OIT with multiple simultaneous allergens. Also, the effect of omalizumab as adjunctive therapy in rush multi OIT had not been investigated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here